Groupe la Francaise
REGN icon

Groupe la Francaise’s Regeneron Pharmaceuticals REGN Stock Holding History

Groupe la Francaise’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
553
+111
+25% +$75.6K ﹤0.01% 375
2026
Q1 		$303K Sell
442
-2,806
-86% -$2.15M ﹤0.01% 356
2025
Q4 		$2.28M Sell
3,248
-783
-19% -$532K 0.03% 239
2025
Q3 		$2.06M Sell
4,031
-325
-7% -$184K 0.03% 245
2025
Q2 		$2.28M Sell
4,356
-3,671
-46% -$2.05M 0.04% 218
2025
Q1 		$4.92M Sell
8,027
-8,034
-50% -$5.53M 0.1% 134
2024
Q4 		$11.7M Buy
+16,061
New +$13.5M 0.29% 54

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Groupe la Francaise's REGN Position: Q2 2026 in Review

Groupe la Francaise increased its Regeneron Pharmaceuticals (REGN) stake by 25% in Q2 2026, buying an estimated $75.6K and bringing the position to 553 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #375.

Groupe la Francaise first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.7M in Q4 2024. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Groupe la Francaise held 553 shares of Regeneron Pharmaceuticals worth $321K as of Q2 2026.
  • Groupe la Francaise bought 111 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $75.6K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Groupe la Francaise's portfolio in Q2 2026, its #375 holding.
  • Groupe la Francaise first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Groupe la Francaise's Regeneron Pharmaceuticals position peaked at $11.7M in Q4 2024.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Groupe la Francaise's 13F filing for Q2 2026, filed 25 Aug 2026.